Leerink Partnrs Has Strong Estimate for KROS FY2025 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Leerink Partnrs upped their FY2025 earnings per share (EPS) estimates for Keros Therapeutics in a research report issued on Tuesday, May 6th. Leerink Partnrs analyst T. Smith now expects that the company will earn $0.94 per share for the year, up from their previous forecast of $0.87. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share.

A number of other equities analysts also recently weighed in on the company. Scotiabank dropped their target price on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a report on Thursday, January 16th. Wedbush reiterated a “neutral” rating and set a $15.00 price objective on shares of Keros Therapeutics in a report on Tuesday, April 1st. Wells Fargo & Company lowered their price target on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, February 27th. HC Wainwright dropped their price target on shares of Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Truist Financial lowered their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, April 9th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Keros Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $38.67.

Keros Therapeutics Stock Down 2.6 %

Shares of Keros Therapeutics stock opened at $13.65 on Thursday. Keros Therapeutics has a 12 month low of $9.12 and a 12 month high of $72.37. The stock has a market cap of $554.39 million, a PE ratio of -2.62 and a beta of 1.32. The business has a fifty day simple moving average of $12.20 and a 200-day simple moving average of $24.71.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $3.63. The business had revenue of $211.25 million for the quarter, compared to the consensus estimate of $84.62 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same period last year, the firm posted ($1.21) earnings per share.

Insiders Place Their Bets

In related news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the firm’s stock in a transaction that occurred on Wednesday, April 9th. The shares were acquired at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the purchase, the insider now directly owns 4,392,737 shares in the company, valued at $44,498,425.81. This represents a 27.01 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 20.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in KROS. Barclays PLC grew its stake in Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock worth $3,484,000 after buying an additional 35,022 shares during the last quarter. SG Americas Securities LLC acquired a new position in Keros Therapeutics in the fourth quarter worth $388,000. Exchange Traded Concepts LLC bought a new stake in shares of Keros Therapeutics during the fourth quarter worth $99,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Keros Therapeutics by 19.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock valued at $136,000 after buying an additional 1,372 shares during the last quarter. Finally, Handelsbanken Fonder AB raised its stake in shares of Keros Therapeutics by 11.3% in the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company’s stock worth $171,000 after acquiring an additional 1,100 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.